Carcinoid tumours of the intestine: Developments in the Netherlands in diagnosis and palliative treatment;Carcinoide tumoren van de darm: Ontwikkelingen binnen Nederland in diagnostiek en palliatieve behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 9, 1999, Pages 445-451

  Taal, B G ^a   Hoefnagel, C ^a   Boot, H ^a   De Jong, D ^a   Rutgers, M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOID; DIARRHEA; FLUSHING; HORMONAL REGULATION; INTESTINE TUMOR; NETHERLANDS; NEUROENDOCRINE TUMOR; PALLIATIVE THERAPY; RECEPTOR BINDING; TUMOR LOCALIZATION; TUMOR VOLUME; CARCINOID SYNDROME; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LIVER TUMOR; MALE; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; REVIEW; SMALL CELL CARCINOMA;

DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CARCINOID HEART DISEASE; CARCINOID TUMOR; CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NETHERLANDS; PALLIATIVE CARE; RADIOPHARMACEUTICALS;

EID: 0033608255     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Graeff A de, Kooijman CD, Obertop H, Lips CJM. Carcinoïde tumoren: nieuwe inzichten in biochemische en endocriene aspecten, diagnostick en behandeling. Ned Tijdschr Geneeskd 1992;136:508-13.
2. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-63.
3. Vries EGE de, Kema IP, Slooff MJH, Verschueren RCJ, Kleibeuker JH, Mulder NH, et al. Recent developments in diagnosis and treatment of metastatic carcinoid tumours. Scand J Gastroenterol Suppl 1993;200:87-93.
4. Kema IP, Vries EGE de, Schellings AM, Postmus PE, Muskiet FAJ. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 1992;38:534-40.
5. Lewin KJ, Kiddell KH, Weinstein WM. Gastrointestinal pathology and its clinical implications. New York/Tokyo: Igaku-Shoin; 1992. p. 197-257.
6. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-81.
7. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H. Combined diagnostic imaging with 131 I-metaiodobenzylguanidine and III Inpentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924-32.
8. Lamberts SWJ, Lely AJ van der, Herder WW de, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
9. Tang C, Biemond I, Lamers CBHW. Expression of peptide receptors in human endocrine tumours of the pancreas. Gut 1997;40:267-71.
10. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991;20:489-95.
11. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6.
12. Lamberts SWJ, Reubi JC, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin Oncol 1994;21(5 Suppl 13):61-4.
13. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somna L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
14. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-8.
15. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83.
16. Veenhof CHN, Wit R de, Taal BG, Dirix LY, Wagstaff J, Hensen A, et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer 1992; 28:75-8.
17. Biesma B, Willemse PHB, Mulder NH, Verschueren RCJ, Kema IP, Bruijn HWA de, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 1992;66:850-5.
18. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647-50.
19. Janson ET, Ronnblom L. Ahlstrom H, Grander D, Alm G, Einhom S, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3:635-8.
20. Andreyev HJN, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-92.
21. 131I-MIBG in animal models. Horm Metab Res 1998 [ter perse].
22. Parckh D, Ishizuka J, Townsend jr CM, Haber B, Beauchamp RD, Karp G, et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 1994;9:83-90.
23. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829-38.
24. Kuin A, Smets L, Volk T, Paans A, Adams G, Atema A. et al. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res 1994;54:3785-92.
25. Smets LA, Bout B, Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol 1988;21:9-13.
26. 131I-MIBG scanning and its potential benefit in the treatment of metastatic carcinoid. Eur J Gastroent Hep 1996;8:A36.
27. Montaldo PG, Carbone R, Ponzoni M, Cornaglia-Ferraris P. gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neurohlastoma cells. Cancer Res 1992;52: 4960-4.
28. Robiolio PA, Rigolin VH, Harrison JK, Lowe JE, Moore JO, Bashore TM, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995;75:485-8.